Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00151073
Status:
COMPLETED
Last Update Posted:
2015-01-22
First Post:
2005-09-06
Brief Title:
Estramustine Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
An Evaluation of Estramustine Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Purpose The aim of this clinical trail is to evaluate the effectiveness of Zoledronate Zometa combined with Estramustine and Docetaxel Taxotere in the treatment of patients with hormone-refractory prostate cancer
Detailed Description:
Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responds to conventional hormonal treatment When hormone therapy is no longer successful chemotherapy is a treatment option However current single-agent treatment has shown to have limited benefit In this clinical trail investigators are evaluating the effectiveness of ZoledronateZometa combined with Estramustine and Docetaxel Taxotere in the treatment of patients with hormone refractory prostate cancer Zometa is a bisphosphonate and may reduce or delay skeletal complications caused by bone metastases Estramustine and Taxotere are chemotherapy drugs that have shown activity in hormone refractory prostate cancer Eligible patients will be randomized to receive Estramustine and Docetaxel Taxotere in combination with Zometa or Zometa given alone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None